Kyverna Therapeutics (KYTX) Competitors $3.53 +0.02 (+0.57%) As of 02:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYTX vs. KROS, BCAX, RLAY, TYRA, SAGE, UPXI, TRML, TERN, RAPP, and BCYCShould you be buying Kyverna Therapeutics stock or one of its competitors? The main competitors of Kyverna Therapeutics include Keros Therapeutics (KROS), Bicara Therapeutics (BCAX), Relay Therapeutics (RLAY), Tyra Biosciences (TYRA), Sage Therapeutics (SAGE), Upexi (UPXI), Tourmaline Bio (TRML), Terns Pharmaceuticals (TERN), Rapport Therapeutics (RAPP), and Bicycle Therapeutics (BCYC). These companies are all part of the "pharmaceutical products" industry. Kyverna Therapeutics vs. Its Competitors Keros Therapeutics Bicara Therapeutics Relay Therapeutics Tyra Biosciences Sage Therapeutics Upexi Tourmaline Bio Terns Pharmaceuticals Rapport Therapeutics Bicycle Therapeutics Keros Therapeutics (NASDAQ:KROS) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends. Do insiders and institutionals hold more shares of KROS or KYTX? 71.6% of Keros Therapeutics shares are owned by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are owned by institutional investors. 22.9% of Keros Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more volatility & risk, KROS or KYTX? Keros Therapeutics has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Kyverna Therapeutics has a beta of 3.05, meaning that its share price is 205% more volatile than the S&P 500. Is KROS or KYTX more profitable? Keros Therapeutics has a net margin of 8.06% compared to Kyverna Therapeutics' net margin of 0.00%. Keros Therapeutics' return on equity of 2.96% beat Kyverna Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Keros Therapeutics8.06% 2.96% 2.74% Kyverna Therapeutics N/A -64.98%-56.17% Does the media refer more to KROS or KYTX? In the previous week, Kyverna Therapeutics had 6 more articles in the media than Keros Therapeutics. MarketBeat recorded 15 mentions for Kyverna Therapeutics and 9 mentions for Keros Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.11 beat Keros Therapeutics' score of -0.09 indicating that Kyverna Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Keros Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kyverna Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts prefer KROS or KYTX? Keros Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 106.61%. Kyverna Therapeutics has a consensus price target of $15.60, suggesting a potential upside of 341.93%. Given Kyverna Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kyverna Therapeutics is more favorable than Keros Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Keros Therapeutics 0 Sell rating(s) 7 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.50Kyverna Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Which has higher valuation and earnings, KROS or KYTX? Kyverna Therapeutics has higher revenue and earnings than Keros Therapeutics. Kyverna Therapeutics is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKeros Therapeutics$3.55M166.14-$187.35M$0.3146.84Kyverna Therapeutics$7.03M21.72-$127.48M-$3.68-0.96 SummaryKeros Therapeutics beats Kyverna Therapeutics on 9 of the 17 factors compared between the two stocks. Get Kyverna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KYTX vs. The Competition Export to ExcelMetricKyverna TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$153.32M$3.13B$5.72B$9.77BDividend YieldN/A2.21%3.77%4.10%P/E Ratio-0.9620.9330.9025.26Price / Sales21.72231.60403.8188.28Price / CashN/A41.5625.2228.45Price / Book0.579.749.516.00Net Income-$127.48M-$54.74M$3.26B$265.34M7 Day Performance13.87%7.94%4.48%2.84%1 Month Performance-9.49%7.52%5.19%1.58%1 Year Performance-47.63%17.41%31.75%25.40% Kyverna Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KYTXKyverna Therapeutics2.1698 of 5 stars$3.53+0.6%$15.60+341.9%-47.9%$153.32M$7.03M-0.9696News CoverageEarnings ReportAnalyst RevisionKROSKeros Therapeutics2.1172 of 5 stars$13.35-2.8%$30.00+124.7%-68.2%$557.65M$3.55M43.07100BCAXBicara TherapeuticsN/A$9.99-2.1%$31.86+218.9%N/A$556.27MN/A0.0032News CoveragePositive NewsEarnings ReportAnalyst RevisionRLAYRelay Therapeutics2.2588 of 5 stars$3.25+0.9%$17.25+430.8%-45.1%$555.16M$10.01M-1.67330TYRATyra Biosciences2.39 of 5 stars$10.10-3.3%$30.83+205.3%-50.6%$554.79MN/A-6.2020News CoveragePositive NewsEarnings ReportUpcoming EarningsSAGESage Therapeutics3.9105 of 5 stars$8.68flat$7.85-9.6%N/A$543.54M$41.24M-1.78690UPXIUpexi2.5404 of 5 stars$5.62-7.0%$15.50+175.8%+84.3%$539.74M$26M0.00130Short Interest ↑TRMLTourmaline Bio2.5653 of 5 stars$20.99+1.3%$49.33+135.0%+61.7%$532.20MN/A-6.5444News CoverageEarnings ReportAnalyst RevisionTERNTerns Pharmaceuticals3.9096 of 5 stars$6.30+3.6%$15.63+148.0%-2.8%$532.07MN/A-6.0640Positive NewsRAPPRapport Therapeutics1.6927 of 5 stars$14.34-1.4%$29.50+105.7%-29.4%$531.04MN/A-5.74N/ABCYCBicycle Therapeutics2.9024 of 5 stars$7.46-2.5%$24.00+221.7%-66.8%$529.79M$35.28M-2.13240Short Interest ↓ Related Companies and Tools Related Companies KROS Alternatives BCAX Alternatives RLAY Alternatives TYRA Alternatives SAGE Alternatives UPXI Alternatives TRML Alternatives TERN Alternatives RAPP Alternatives BCYC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KYTX) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyverna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access